Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice

被引:0
|
作者
Zhijun Fan [1 ]
Zheng Yi [1 ]
Sheng Li [2 ]
Junjun He [2 ]
机构
[1] Department of Cardiothoracic Surgery, The People’s Hospital of Liuyang, Changsha
[2] Department of Gastrointestinal Surgery, The Central Hospital of Shaoyang, Shaoyang
关键词
CXCL9; Non-small cell lung cancer; Parabacteroides distasonis; PD-1; Tumor-associated macrophages;
D O I
10.1186/s12896-025-00963-9
中图分类号
学科分类号
摘要
Background: Parabacteroides distasonis (P. distasonis) could regulate inflammatory markers, promote intestinal barrier integrity, and block tumor formation in colon. However, the regulatory effect of P. distasonis on non-small cell lung cancer (NSCLC) remains unknown. This study aimed to investigate the regulatory effect of P. distasonis on NSCLC and its impact on tumor immunity. Methods: We first established a mouse model of Lewis lung cancer, and administered P. distasonis and intrabitoneal injection of anti-mouse PD-1 monoclonal antibody to assess the impact of P. distasonis on tumor immunity, and mouse intestinal barrier. Then, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secretion mediated by tumor-associated macrophages (TAM). We used the TLR1/2 complex inhibitor CPT22 to evaluate its effect on macrophage activation. Finally, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secreted by TAM in vivo. Results: In vivo, P. distasonis enhanced anti-tumor effects of anti-PD-1 in NSCLC mice, improved intestinal barrier integrity, recruited macrophages, and promoted M1 polarization. In vitro, CD86 and iNOS levels in BMDM were elevated and CD206 and Arg1 levels were suppressed in membrane fraction of P. distasonis (PdMb) group in comparison to Control group. With additional CPT22 pre-treatment, the levels of CD86 and iNOS in BMDM were reduced, and the levels of CD206 and Arg1 were increased. Compared to PBS group, P. distasonis group exhibited higher proportion of CD8+T cells in tumor tissues, along with increased positive proportion of GZMB and IFN-γ in CD8+T cells. Additionally, in comparison to Control group, PdMb group showed an elevated proportion of GZMB+T and IFN-γ+T cells within CD8+T cells, and secretion of IFN-γ, TNF-α, perforin, and GZMB in CD8+T cell supernatant increased. Moreover, the proportion of CXCL9+F4/80+ macrophages in tumor tissues was higher in P. distasonis group compared to PBS group. In comparison to Control group, CXCL9 protein level in BMDM and CXCL9 secretion level in BMDM supernatant were increased in PdMb group. Finally, P. distasonis enhanced CD8+T cell activity by secreting CXCL9 from macrophages in vivo. Conclusions: P. distasonis promoted CXCL9 secretion of TAM and enhanced CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in NSCLC mice. © The Author(s) 2025.
引用
收藏
相关论文
共 35 条
  • [1] Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer
    Bei Zuo
    Tao Li
    Xiaoyun Liu
    Shuling Wang
    Jianxiang Cheng
    Xiangqun Liu
    Wenjie Cui
    Hengliang Shi
    Chunhua Ling
    Clinical and Translational Oncology, 2023, 25 : 3188 - 3202
  • [2] Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer
    Zuo, Bei
    Li, Tao
    Liu, Xiaoyun
    Wang, Shuling
    Cheng, Jianxiang
    Liu, Xiangqun
    Cui, Wenjie
    Shi, Hengliang
    Ling, Chunhua
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (11) : 3188 - 3202
  • [3] The In Vitro Anti-Tumor Activity of Phycocyanin against Non-Small Cell Lung Cancer Cells
    Hao, Shuai
    Yan, Yan
    Li, Shuang
    Zhao, Lei
    Zhang, Chan
    Liu, Liyun
    Wang, Chengtao
    MARINE DRUGS, 2018, 16 (06)
  • [4] Down-Regulation of HBXIP Inhibits Non-Small Cell Lung Cancer Growth and Enhances the Anti-Tumor Immunity of Mice by Reducing NRP-1
    Wang, Lulu
    Sun, Mao
    Lin, Xing
    Lei, Yongyang
    Yin, Zhe
    Zhou, Wei
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (04) : 487 - 493
  • [5] Hirsutella sinensis Fungus Promotes CD8+ T Cell-Mediated Anti-Tumor Immunity by Affecting Tumor-Associated Macrophages-Derived CCRL2
    Zhao, Kaixiang
    Ma, Yan
    Luo, Jing
    Xu, Yanhui
    Shou, Qiyang
    Jiang, Hao
    Zhu, Xinhai
    IMMUNOLOGICAL INVESTIGATIONS, 2025,
  • [6] PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF TUMOR LOCATION IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ANTI-PD-1 THERAPY
    Takamori, S.
    Takada, K.
    Shimokawa, M.
    Matsubara, T.
    Haratake, N.
    Miura, N.
    Toyozawa, R.
    Yamaguchi, M.
    Takenoyama, M.
    Okamoto, I.
    Tagawa, T.
    Mori, M.
    CHEST, 2020, 157 (06) : 234A - 234A
  • [7] Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer
    Wang, Wei
    Kong, Min
    Shen, Fu
    Li, Ping
    Chen, Cheng
    Li, Yueqin
    Li, Cheng
    Qian, Zhiqiang
    Zhong, Aihua
    Wang, Yuhua
    Yang, Liang
    He, Fangkai
    Li, Weichun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment
    Zhuang, Zhan
    Zhou, Jinglin
    Qiu, Minglian
    Li, Jiamian
    Lin, Zhuangheng
    Yi, Huihan
    Liu, Xuerong
    Huang, Changyu
    Tang, Binghua
    Liu, Bo
    Li, Xu
    CANCERS, 2024, 16 (04)
  • [9] CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus
    Qu, Jingjing
    Li, Yuekang
    Wu, Binggen
    Shen, Qian
    Chen, Lijun
    Sun, Wenjia
    Wang, Bo
    Ying, Lixiong
    Wu, Li
    Zhou, Hong
    Zhou, Jianya
    Zhou, Jianying
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [10] Inhibition of Stearoyl-CoA Desaturase 1 Potentiates Anti-tumor Activity of Amodiaquine in Non-small Cell Lung Cancer
    Hu, Xiaolei
    Xiang, Jiangning
    Li, Yibo
    Xia, Yan
    Xu, Siyuan
    Gao, Xiaoge
    Qiao, Shuxi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (04) : 438 - 445